New calculation tool identifies a group of cancer patients with favorable prognosis

Researchers at the Cima University of Navarra (Spain), in collaboration with the Spanish Myeloma Group (GEM-PETHEMA), have developed a calculator that identifies patients with multiple myeloma and primary systemic amyloidosis who have a better prognosis because they have a more benign profile. This tool could become part of the diagnostic workup of these patients.